Bambusa Therapeutics Announces $168.89 Million IPO

BOSTON, Oct. 29, 2026 /CourierPR/ -- Bambusa Therapeutics, a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies, has announced the pricing of its upsized initial public offering. The company is offering 10,555,555 shares of its common stock at a public offering price of $16.00 per share, with gross proceeds expected to amount to $168,888,880. Bambusa has also granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The company's common stock is expected to begin trading on the Nasdaq Global Select Market on October 30, 2026, under the ticker symbol "BBTX." The offering is expected to close on November 2, 2026, subject to the satisfaction of customary closing conditions. The registration statements relating to the offering became effective on October 29, 2026.

Bambusa Therapeutics is focused on developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation. The company combines third-party, advanced antibody engineering and clinically and commercially validated biologic pathways into a single molecule, formulated for high-concentration subcutaneous delivery to improve durability, convenience, and clinical differentiation beyond the current capabilities of existing monotherapies.

The company's pipeline includes BBT001, a bispecific antibody targeting IL-4Rα and IL-31, currently in clinical development for atopic dermatitis and other inflammatory skin diseases. BBT002, another bispecific antibody targeting IL-4Rα and IL-5, is in clinical development for Type 2 inflammatory disorders. Additionally, Bambusa has preclinical programs BBT003 and BBT004, which are focused on gastroenterology and autoantibody-driven autoimmune diseases, respectively.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the commencement of trading of Bambusa's shares of common stock on the Nasdaq Global Select Market, the closing of the initial public offering, and the potential advantages of Bambusa's product candidates.